Non-peptide Inhibitors of Proprotein Convertase Subtilisin Kexins (PCSKs) (Colloquium Series on Protein Activation and Cancer)

0 avg rating
( 0 ratings by Goodreads )
 
9781615044740: Non-peptide Inhibitors of Proprotein Convertase Subtilisin Kexins (PCSKs) (Colloquium Series on Protein Activation and Cancer)
View all copies of this ISBN edition:
 
 

The Ca+2-dependent mammalian Proprotein Convertase Subtilisin Kexins (PCSKs) or Proprotein/ Prohormone Convertases (PCs) are a family of endoproteases that play critical roles not only in normal development and metabolism but also in various physiological and pathological conditions. These were initiated by the proteolytic processing of large inactive proproteins into their shorter bioactive mature forms by the PCSK enzymes. These events take place in a highly selective, orchestrated, and stepwise manner. Among the various proprotein substrates of PCSK enzymes, particularly important are the precursor growth factors that include proPDGF-A, B, proIGF-1, 2 and proVEGF-C because of their strong implications in neoplasia initiation, progression, and metastasis. As a result of these findings, PCSK enzymes, particularly furin or PCSK3, became a major target for possible interventions of cancer via the use of their selective inhibitors. Significant progress has been accomplished in the development of peptide and protein-based PCSK inhibitors. However, non-peptide PCSK9 inhibitors are more preferable because of their drug-like and other characteristics. So far, a few non-peptide inhibitors of PCSK enzymes of various types of chemical structures have been described in the literature. These include (i) Carbocyclic compounds of diterpene and streptamine class. (ii) Nitrogen (N)-based heterocyclic compounds of various types and chemical structures such as (a) pyrrolidine bis piperazines, (b) Cu/Zn chelating terpyridine derivatives; (iii) Oxygen (O)-based Heterocyclic compounds of varying types of chemical structures such as (a) Flavonoids, (b) Coumarins of simple and dimeric types, (c) Quinonoids, (d) Iridoids; (iv) Aromatic compounds such as (a) Aryl guanidino and amidino derivatives, (b) Naphthyl fluorescein derivative, and (c) Phenyl Arsonic acids; and (v) C2-symmetrical aromatic azo-compounds. When measured against a small peptidyl-MCA fluorogenic substrate, these inhibitors displayed IC50 values ranging from nM to μM. A number of these inhibitors exhibited significant anti-PCSK activity when tested in ex vivo or cell culture conditions. This article provides an overall review of all non-peptide PCSK inhibitors so far reported in the literature along with those we identified recently for the first time and not yet published. The potential implications of these molecules as biochemical, therapeutical, or clinical agents will also be discussed.

Table of Contents: Introduction / Historical Perspectives / Class of PCSK Inhibitors / Comparative Analyses of Peptide and Non-peptide Inhibitors / Class of Non-peptide Inhibitors of PCSKs / Comparison of Activities of Non-peptide Inhibitors of PCSK Enzymes / Blockade of Proprotein Processing by Non-peptide PCSK Inhibitors in Cellular Models / Animal Study with Non-peptide PCSK Inhibitors / Future Perspectives of Non-peptide PCSK Inhibitors and Concluding Remarks / Acknowledgments / References

"synopsis" may belong to another edition of this title.

About the Author:

Research Director, INSERM, and, University of Bordeaux

"About this title" may belong to another edition of this title.

Buy New View Book
List Price: US$ 40.00
US$ 47.11

Convert currency

Shipping: FREE
From United Kingdom to U.S.A.

Destination, rates & speeds

Add to Basket

Top Search Results from the AbeBooks Marketplace

1.

Utpal Chandra De, Priyambada Mishra, Prasenjit Rudra Pal
Published by Morgan Claypool Publishers, United States (2012)
ISBN 10: 1615044744 ISBN 13: 9781615044740
New Paperback Quantity Available: 10
Print on Demand
Seller:
Book Depository International
(London, United Kingdom)
Rating
[?]

Book Description Morgan Claypool Publishers, United States, 2012. Paperback. Condition: New. Language: English . Brand New Book ***** Print on Demand *****. The Ca+2-dependent mammalian Proprotein Convertase Subtilisin Kexins (PCSKs) or Proprotein/ Prohormone Convertases (PCs) are a family of endoproteases that play critical roles not only in normal development and metabolism but also in various physiological and pathological conditions. These were initiated by the proteolytic processing of large inactive proproteins into their shorter bioactive mature forms by the PCSK enzymes. These events take place in a highly selective, orchestrated, and stepwise manner. Among the various proprotein substrates of PCSK enzymes, particularly important are the precursor growth factors that include proPDGF-A, B, proIGF-1, 2 and proVEGF-C because of their strong implications in neoplasia initiation, progression, and metastasis. As a result of these findings, PCSK enzymes, particularly furin or PCSK3, became a major target for possible interventions of cancer via the use of their selective inhibitors. Significant progress has been accomplished in the development of peptide and protein-based PCSK inhibitors. However, non-peptide PCSK9 inhibitors are more preferable because of their drug-like and other characteristics. So far, a few non-peptide inhibitors of PCSK enzymes of various types of chemical structures have been described in the literature. These include (i) Carbocyclic compounds of diterpene and streptamine class. (ii) Nitrogen (N)-based heterocyclic compounds of various types and chemical structures such as (a) pyrrolidine bis piperazines, (b) Cu/Zn chelating terpyridine derivatives; (iii) Oxygen (O)-based Heterocyclic compounds of varying types of chemical structures such as (a) Flavonoids, (b) Coumarins of simple and dimeric types, (c) Quinonoids, (d) Iridoids; (iv) Aromatic compounds such as (a) Aryl guanidino and amidino derivatives, (b) Naphthyl fluorescein derivative, and (c) Phenyl Arsonic acids; and (v) C2-symmetrical aromatic azo-compounds. When measured against a small peptidyl-MCA fluorogenic substrate, these inhibitors displayed IC50 values ranging from nM to ?M. A number of these inhibitors exhibited significant anti-PCSK activity when tested in ex vivo or cell culture conditions. This article provides an overall review of all non-peptide PCSK inhibitors so far reported in the literature along with those we identified recently for the first time and not yet published. The potential implications of these molecules as biochemical, therapeutical, or clinical agents will also be discussed. Seller Inventory # APC9781615044740

More information about this seller | Contact this seller

Buy New
US$ 47.11
Convert currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, rates & speeds

2.

Uptal Chandra De
Published by Morgan & Claypool Life Sciences
ISBN 10: 1615044744 ISBN 13: 9781615044740
New Paperback Quantity Available: > 20
Seller:
BuySomeBooks
(Las Vegas, NV, U.S.A.)
Rating
[?]

Book Description Morgan & Claypool Life Sciences. Paperback. Condition: New. 76 pages. Dimensions: 9.2in. x 7.5in. x 0.2in.The Ca2-dependent mammalian Proprotein Convertase Subtilisin Kexins (PCSKs) or Proprotein Prohormone Convertases (PCs) are a family of endoproteases that play critical roles not only in normal development and metabolism but also in various physiological and pathological conditions. These were initiated by the proteolytic processing of large inactive proproteins into their shorter bioactive mature forms by the PCSK enzymes. These events take place in a highly selective, orchestrated, and stepwise manner. Among the various proprotein substrates of PCSK enzymes, particularly important are the precursor growth factors that include proPDGF-A, B, proIGF-1, 2 and proVEGF-C because of their strong implications in neoplasia initiation, progression, and metastasis. As a result of these findings, PCSK enzymes, particularly furin or PCSK3, became a major target for possible interventions of cancer via the use of their selective inhibitors. Significant progress has been accomplished in the development of peptide and protein-based PCSK inhibitors. However, non-peptide PCSK9 inhibitors are more preferable because of their drug-like and other characteristics. So far, a few non-peptide inhibitors of PCSK enzymes of various types of chemical structures have been described in the literature. These include (i) Carbocyclic compounds of diterpene and streptamine class. (ii) Nitrogen (N)-based heterocyclic compounds of various types and chemical structures such as (a) pyrrolidine bis piperazines, (b) CuZn chelating terpyridine derivatives; (iii) Oxygen (O)-based Heterocyclic compounds of varying types of chemical structures such as (a) Flavonoids, (b) Coumarins of simple and dimeric types, (c) Quinonoids, (d) Iridoids; (iv) Aromatic compounds such as (a) Aryl guanidino and amidino derivatives, (b) Naphthyl fluorescein derivative, and (c) Phenyl Arsonic acids; and (v) C2-symmetrical aromatic azo-compounds. When measured against a small peptidyl-MCA fluorogenic substrate, these inhibitors displayed IC50 values ranging from nM to M. A number of these inhibitors exhibited significant anti-PCSK activity when tested in ex vivo or cell culture conditions. This article provides an overall review of all non-peptide PCSK inhibitors so far reported in the literature along with those we identified recently for the first time and not yet published. The potential implications of these molecules as biochemical, therapeutical, or clinical agents will also be discussed. Table of Contents: Introduction Historical Perspectives Class of PCSK Inhibitors Comparative Analyses of Peptide and Non-peptide Inhibitors Class of Non-peptide Inhibitors of PCSKs Comparison of Activities of Non-peptide Inhibitors of PCSK Enzymes Blockade of Proprotein Processing by Non-peptide PCSK Inhibitors in Cellular Models Animal Study with Non-peptide PCSK Inhibitors Future Perspectives of Non-peptide PCSK Inhibitors and Concluding Remarks Acknowledgments References This item ships from multiple locations. Your book may arrive from Roseburg,OR, La Vergne,TN. Paperback. Seller Inventory # 9781615044740

More information about this seller | Contact this seller

Buy New
US$ 51.62
Convert currency

Add to Basket

Shipping: FREE
Within U.S.A.
Destination, rates & speeds

3.

Priyambada Mishra, Prasenjit Rudra Pal, Utpal Chandra De,
Published by Morgan & Claypool Publishers, United States (2012)
ISBN 10: 1615044744 ISBN 13: 9781615044740
New Paperback Quantity Available: 10
Seller:
The Book Depository
(London, United Kingdom)
Rating
[?]

Book Description Morgan & Claypool Publishers, United States, 2012. Paperback. Condition: New. Language: English. Brand new Book. The Ca+2-dependent mammalian Proprotein Convertase Subtilisin Kexins (PCSKs) or Proprotein/ Prohormone Convertases (PCs) are a family of endoproteases that play critical roles not only in normal development and metabolism but also in various physiological and pathological conditions. These were initiated by the proteolytic processing of large inactive proproteins into their shorter bioactive mature forms by the PCSK enzymes. These events take place in a highly selective, orchestrated, and stepwise manner. Among the various proprotein substrates of PCSK enzymes, particularly important are the precursor growth factors that include proPDGF-A, B, proIGF-1, 2 and proVEGF-C because of their strong implications in neoplasia initiation, progression, and metastasis. As a result of these findings, PCSK enzymes, particularly furin or PCSK3, became a major target for possible interventions of cancer via the use of their selective inhibitors. Significant progress has been accomplished in the development of peptide and protein-based PCSK inhibitors. However, non-peptide PCSK9 inhibitors are more preferable because of their drug-like and other characteristics. So far, a few non-peptide inhibitors of PCSK enzymes of various types of chemical structures have been described in the literature. These include (i) Carbocyclic compounds of diterpene and streptamine class. (ii) Nitrogen (N)-based heterocyclic compounds of various types and chemical structures such as (a) pyrrolidine bis piperazines, (b) Cu/Zn chelating terpyridine derivatives; (iii) Oxygen (O)-based Heterocyclic compounds of varying types of chemical structures such as (a) Flavonoids, (b) Coumarins of simple and dimeric types, (c) Quinonoids, (d) Iridoids; (iv) Aromatic compounds such as (a) Aryl guanidino and amidino derivatives, (b) Naphthyl fluorescein derivative, and (c) Phenyl Arsonic acids; and (v) C2-symmetrical aromatic azo-compounds. When measured against a small peptidyl-MCA fluorogenic substrate, these inhibitors displayed IC50 values ranging from nM to ?M. A number of these inhibitors exhibited significant anti-PCSK activity when tested in ex vivo or cell culture conditions. This article provides an overall review of all non-peptide PCSK inhibitors so far reported in the literature along with those we identified recently for the first time and not yet published. The potential implications of these molecules as biochemical, therapeutical, or clinical agents will also be discussed. Seller Inventory # APC9781615044740

More information about this seller | Contact this seller

Buy New
US$ 57.08
Convert currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, rates & speeds

4.

Priyambada Mishra, Prasenjit Rudra Pal, Utpal Chandra De,
Published by Morgan & Claypool Publishers, United States (2012)
ISBN 10: 1615044744 ISBN 13: 9781615044740
New Paperback Quantity Available: 10
Seller:
Book Depository hard to find
(London, United Kingdom)
Rating
[?]

Book Description Morgan & Claypool Publishers, United States, 2012. Paperback. Condition: New. Language: English. Brand new Book. The Ca+2-dependent mammalian Proprotein Convertase Subtilisin Kexins (PCSKs) or Proprotein/ Prohormone Convertases (PCs) are a family of endoproteases that play critical roles not only in normal development and metabolism but also in various physiological and pathological conditions. These were initiated by the proteolytic processing of large inactive proproteins into their shorter bioactive mature forms by the PCSK enzymes. These events take place in a highly selective, orchestrated, and stepwise manner. Among the various proprotein substrates of PCSK enzymes, particularly important are the precursor growth factors that include proPDGF-A, B, proIGF-1, 2 and proVEGF-C because of their strong implications in neoplasia initiation, progression, and metastasis. As a result of these findings, PCSK enzymes, particularly furin or PCSK3, became a major target for possible interventions of cancer via the use of their selective inhibitors. Significant progress has been accomplished in the development of peptide and protein-based PCSK inhibitors. However, non-peptide PCSK9 inhibitors are more preferable because of their drug-like and other characteristics. So far, a few non-peptide inhibitors of PCSK enzymes of various types of chemical structures have been described in the literature. These include (i) Carbocyclic compounds of diterpene and streptamine class. (ii) Nitrogen (N)-based heterocyclic compounds of various types and chemical structures such as (a) pyrrolidine bis piperazines, (b) Cu/Zn chelating terpyridine derivatives; (iii) Oxygen (O)-based Heterocyclic compounds of varying types of chemical structures such as (a) Flavonoids, (b) Coumarins of simple and dimeric types, (c) Quinonoids, (d) Iridoids; (iv) Aromatic compounds such as (a) Aryl guanidino and amidino derivatives, (b) Naphthyl fluorescein derivative, and (c) Phenyl Arsonic acids; and (v) C2-symmetrical aromatic azo-compounds. When measured against a small peptidyl-MCA fluorogenic substrate, these inhibitors displayed IC50 values ranging from nM to ?M. A number of these inhibitors exhibited significant anti-PCSK activity when tested in ex vivo or cell culture conditions. This article provides an overall review of all non-peptide PCSK inhibitors so far reported in the literature along with those we identified recently for the first time and not yet published. The potential implications of these molecules as biochemical, therapeutical, or clinical agents will also be discussed. Seller Inventory # TNP9781615044740

More information about this seller | Contact this seller

Buy New
US$ 57.08
Convert currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, rates & speeds

5.

Utpal Chandra De; Priyambada Mishra; Prasenjit Rudra Pal
Published by Morgan & Claypool Life Sciences (2012)
ISBN 10: 1615044744 ISBN 13: 9781615044740
New Softcover Quantity Available: 15
Print on Demand
Seller:
Rating
[?]

Book Description Morgan & Claypool Life Sciences, 2012. Condition: New. This item is printed on demand for shipment within 3 working days. Seller Inventory # LP9781615044740

More information about this seller | Contact this seller

Buy New
US$ 58.84
Convert currency

Add to Basket

Shipping: US$ 3.43
From Germany to U.S.A.
Destination, rates & speeds

6.

Chandra De, Utpal
Published by Morgan & Claypool Life Sciences (2016)
ISBN 10: 1615044744 ISBN 13: 9781615044740
New Paperback Quantity Available: 1
Print on Demand
Seller:
Ria Christie Collections
(Uxbridge, United Kingdom)
Rating
[?]

Book Description Morgan & Claypool Life Sciences, 2016. Paperback. Condition: New. PRINT ON DEMAND Book; New; Publication Year 2016; Not Signed; Fast Shipping from the UK. No. book. Seller Inventory # ria9781615044740_lsuk

More information about this seller | Contact this seller

Buy New
US$ 57.37
Convert currency

Add to Basket

Shipping: US$ 5.04
From United Kingdom to U.S.A.
Destination, rates & speeds

7.

De, Utpal Chandra/ Mishra, Priyambada/ Pal, Prasenjit/ Dinda, Biswanath/ Basak, Ajoy
Published by Morgan & Claypool (2012)
ISBN 10: 1615044744 ISBN 13: 9781615044740
New Paperback Quantity Available: 2
Seller:
Revaluation Books
(Exeter, United Kingdom)
Rating
[?]

Book Description Morgan & Claypool, 2012. Paperback. Condition: Brand New. 1st edition. 76 pages. 9.25x7.50x0.25 inches. In Stock. Seller Inventory # x-1615044744

More information about this seller | Contact this seller

Buy New
US$ 53.33
Convert currency

Add to Basket

Shipping: US$ 9.77
From United Kingdom to U.S.A.
Destination, rates & speeds

8.

DE, MISHRA, PAL & BASAK
Published by Morgan & Claypool Publishers (2012)
ISBN 10: 1615044744 ISBN 13: 9781615044740
New Paperback Quantity Available: 1
Seller:
Herb Tandree Philosophy Books
(Stroud, GLOS, United Kingdom)
Rating
[?]

Book Description Morgan & Claypool Publishers, 2012. Paperback. Condition: NEW. 9781615044740 This listing is a new book, a title currently in-print which we order directly and immediately from the publisher. For all enquiries, please contact Herb Tandree Philosophy Books directly - customer service is our primary goal. Seller Inventory # HTANDREE01112729

More information about this seller | Contact this seller

Buy New
US$ 54.32
Convert currency

Add to Basket

Shipping: US$ 10.42
From United Kingdom to U.S.A.
Destination, rates & speeds

9.

Uptal Chandra De; Priyambada Mishra; Prasenjit Rudra Pal; Biswanath Dinda; Ajoy Basak
Published by Morgan & Claypool Life Sciences (2012)
ISBN 10: 1615044744 ISBN 13: 9781615044740
New Softcover Quantity Available: 1
Seller:
Irish Booksellers
(Portland, ME, U.S.A.)
Rating
[?]

Book Description Morgan & Claypool Life Sciences, 2012. Condition: New. book. Seller Inventory # M1615044744

More information about this seller | Contact this seller

Buy New
US$ 63.80
Convert currency

Add to Basket

Shipping: US$ 3.27
Within U.S.A.
Destination, rates & speeds

10.

Uptal Chandra De
Published by Morgan & Claypool Life Sciences (2012)
ISBN 10: 1615044744 ISBN 13: 9781615044740
New Paperback Quantity Available: 1
Seller:
Books Express
(Portsmouth, NH, U.S.A.)
Rating
[?]

Book Description Morgan & Claypool Life Sciences, 2012. Paperback. Condition: New. 1. Ships with Tracking Number! INTERNATIONAL WORLDWIDE Shipping available. Buy with confidence, excellent customer service!. Seller Inventory # 1615044744n

More information about this seller | Contact this seller

Buy New
US$ 170.49
Convert currency

Add to Basket

Shipping: FREE
Within U.S.A.
Destination, rates & speeds